Current Issue
Volumes and Issues
For Authors
Manuscript Guidelines
Review Process
Conflict of Interest
Copyright
About the Journal
Editorial Board
Aim and Scope
Policy and Ethical Guidelines
Promotion of the Journal
Print-Version Subscription
Publisher and Contact Information
Contact Information
Sign in as an AUTHOR/REVIEWER
ORIGINAL ARTICLE
NEUROPLASTICITY AFTER COCHLEAR IMPLANTATION AS ASSESSED BY THE PLASMA LEVEL OF MMP-9 AND ITS GENETIC POLYMORPHISMS: A PROSPECTIVE STUDY OF CONGENITALLY DEAF CHILDREN
1
Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Warsaw, Poland
2
Department of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland
3
Laboratory of Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
Submission date: 2022-05-18
Final revision date: 2022-08-05
Acceptance date: 2022-08-30
Publication date: 2022-09-30
Corresponding author
Monika Matusiak
Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Mochanckiego 10, 02-042, Warsaw, Poland
Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Mochanckiego 10, 02-042, Warsaw, Poland
J Hear Sci 2022;12(3):47-53
KEYWORDS
TOPICS
ABSTRACT
Background:
If it was possible to assay biomarkers of neuroplasticity it might facilitate clinical management of deaf implanted children by identifying those among them who are at risk of speech and language rehabilitation failure. MMP9 is a proteinase involved in neuroplasticity underlying different clinical conditions in human.
Material and methods:
This was a longitudinal, prospective cohort study of 61 congenitally deaf children who underwent cochlear implantation. We investigated the genetic variants of matrix metalloproteinase 9 (MMP9) and plasma levels of MMP-9 that have been implicated in neuroplasticity after cochlear implantation. Auditory development was assessed by using the LittlEARS Questionnaire (LEAQ) at three follow-up points and the plasma level of MMP-9 was measured at implantation.
Results:
There was a significant negative correlation between MMP-9 plasma level at implantation and LEAQ score at 18 months follow-up (p < 0.05). Two clusters of good and poor CI performers could be isolated based on this correlation. The prevalence of genetic variants of MMP9 – rs3918242, rs20544, and rs2234681 – in the good performers cluster was different to their prevalence in the poor performers cluster.
Conclusions:
The study showed that children born deaf who have an MMP-9 plasma level of less than 150 ng/ml at cochlear implantation have a reasonable chance of attaining a high LEAQ score after 18 months of speech and language rehabilitation. It appears that MMP-9 plasma level at cochlear implantation is a promising prognostic marker for CI outcome.
If it was possible to assay biomarkers of neuroplasticity it might facilitate clinical management of deaf implanted children by identifying those among them who are at risk of speech and language rehabilitation failure. MMP9 is a proteinase involved in neuroplasticity underlying different clinical conditions in human.
Material and methods:
This was a longitudinal, prospective cohort study of 61 congenitally deaf children who underwent cochlear implantation. We investigated the genetic variants of matrix metalloproteinase 9 (MMP9) and plasma levels of MMP-9 that have been implicated in neuroplasticity after cochlear implantation. Auditory development was assessed by using the LittlEARS Questionnaire (LEAQ) at three follow-up points and the plasma level of MMP-9 was measured at implantation.
Results:
There was a significant negative correlation between MMP-9 plasma level at implantation and LEAQ score at 18 months follow-up (p < 0.05). Two clusters of good and poor CI performers could be isolated based on this correlation. The prevalence of genetic variants of MMP9 – rs3918242, rs20544, and rs2234681 – in the good performers cluster was different to their prevalence in the poor performers cluster.
Conclusions:
The study showed that children born deaf who have an MMP-9 plasma level of less than 150 ng/ml at cochlear implantation have a reasonable chance of attaining a high LEAQ score after 18 months of speech and language rehabilitation. It appears that MMP-9 plasma level at cochlear implantation is a promising prognostic marker for CI outcome.
REFERENCES (31)
1.
Kral A, O’Donoghue G. Profound deafness in childhood. N Eng J Med, 2010; 363: 1438–50.
2.
Kral A, Kronenberger WG, Pisoni DB, O’Donoghue GM. Neurocognitive factors in sensory restoration of early deafness: a connectome model. Lancet Neurol, 2016; 15(6): 610–21.
3.
Niparko J, Tobey EA, Thal DJ, Eisenbrg LS, Wang NY, Quittner AL, et al. Spoken language development in children following cochlear implantation. JAMA, 2010; 303(15): 1498–506.
4.
Houston DM, Stewart J, Moberly A, Hollich G, Miyamoto RT. Word learning in deaf children with cochlear implants: effects of early auditory experience. Dev Sci, 2012; 15: 448–61.
5.
Dettman SJ, Pinder D, Briggs RJS, Dowell RC, Leigh JR. Communication development in children who receive the cochlear implant younger than 12 months: risks versus benefits. Ear Hear, 2007; 28 (Suppl 2): 11S–18S.
6.
Fallon JB, Irvine DRF, Shepherd RK. Neural prostheses and brain plasticity. J Neural Eng, 2009; 6: 065008.
7.
Kral A. Auditory critical periods: a review from system’s perspective. Neurosci, 2013; 247: 117–33.
8.
Holtmaat A, Caroni P. Functional and structural underpinnings of neuronal assembly formation in learning. Nature Neurosci, 2016; 19: 1553–62.
9.
Reinhard SM, Razak K, Ethell I. A delicate balance: role of MMP9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci, 2015.
10.
Beroun A, Mitra S, Michaluk P, Pijet B, Stefaniuk M, Kaczmarek L. MMPs in learning and memory and neuropsychiatric disorders. Cell Mol Life Sci, 2019; 76: 3207–28.
11.
Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem, 2016; 139 (Suppl 2): 91–114.
12.
Ethel IM, Ethel DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res, 2007; 85: 2813–23.
13.
Nagy V, Bozdagy O, Matynia A, Balcerzak M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci, 2006; 26: 1923–34.
14.
Nagy V, Bozdagy O, Huntley WH. The extracellular protease matrix metalloproteinase-9 is required by inhibitory avoidance learning and required for long term memory. Learn Mem, 2007; 14: 655–64.
15.
Bozdagy O, Nagy V, Kwei KT, Huntley GW. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol, 2007; 98: 334–44.
16.
Matusiak M, Oziębło D, Obrycka A, Ołdak M, Kaczmarek L, Skarżyński P, Skarżyński H. Functional polymorphism of MMP9 and BDNF as a potential biomarker of auditory plasticity in prelingual deafness treatment with cochlear implantation: a retrospective cohort analysis. Trends Hear, 2021; 23312165211002140.
17.
Matusiak M, Oziębło D, Ołdak M, Rejmak E, Kaczmarek L, Skarżyński PH, Skarżyński H. Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment. Mol Neurobiol, 2022; 59(4): 2190–203.
18.
Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J Affect Disord, 2013; 146: 286–9.
19.
Matusiak M, Oziębło D, Ołdak M, Rejmak E, Kaczmarek L, Dobek D, et al. MMP-9 plasma level as a biomarker of cochlear implantation outcome: results of a prospective, longitudinal study of congenitally deaf children [preprint]. Available at https://doi.org/10.21203/rs.3..... Accessed 2022 Sept 19.
20.
Weichbold V, Tsiakpini L, Coninx F, D’Haese P. Development of a parent questionnaire for assessment of auditory behaviour of infants up to two years of age. Laryngo-Rhino-Otol, 2005; 84: 328–34.
21.
Obrycka A, Padilla Garcia JP, Pankowska A, Lorens A, Skarżyński H. Production and evaluation of a Polish version of the LittlEars questionnaire for the assessment of auditory development in infants. Int J Pediatr Otorhinolaryngol, 2009; 73: 1035–42.
22.
Coninx F, Weichbold V, Tsiakpini L, Autrique E, Bescond G, Tamas L, et al. Validation of the LittlEARS Auditory Questionnaire in children with normal hearing. Int J Pediatr Otorhinolaryngol, 2009; 73: 1761–68.
23.
Geal-Dor M, Jbarah R, Meilijson S, Adelman C, Levi H. The Hebrew and the Arabic version of the LittlEARS Auditory Questionnaire for the assessment of auditory development: results in normal hearing children and children with cochlear implants. Int J Pediatr Otorhinolaryngol, 2011; 75: 1327–32.
24.
Wanga L, Sun X, Liang W, Chen J, Zheng W. Validation of the Mandarin version of the LittlEARS Auditory Questionnaire. Int J Pediatr Otorhinolaryngol, 2013; 77: 1350–54.
25.
García Negro AS, Padilla García JL, Sainz Quevedo M. Production and evaluation of a Spanish version of the LittlEARS Auditory Questionnaire for the assessment of auditory development in children. Int J Pediatr Otorhinolaryngol, 2016; 83: 99–103.
26.
Obrycka A, Lorens A, Padilla JL, Piotrowska A, Skarżyński H. Validation of the LittlEARS Auditory Questionnaire in cochlear implanted infants and toddlers. Int J Pediatr Otorhinolaryngol, 2017; 93: 107–16.
27.
Kaufman L, Rousseeuw PJ. Finding Groups in Data: An introduction to cluster analysis. Wiley Series in Probability and Statistics, New York: Wiley; 1990.
28.
Xia Q-R, Zhang C, Liang J, Xu Y-Y, 2019. The association of functional polymorphism of matrix metalloproteinase-9 gene (rs3918242) with schizophrenia: a meta-analysis. Int J Psychiatry Clin Pract, 23(3): 207–14.
29.
McGregor N, Thompson N, O’Connell KS, Emsley R, van der Merwe L, Warnich L. Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene and its variants in a first-episode schizophrenia cohort. Psychiatry Res, 2018; 262: 141–8.
30.
Łepeta K, Purzycka KJ, Pachulska-Wieczorek K, et al. A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Mol Med, 2017; 9(8): 1100–6.
31.
Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP-9) does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta Mar, 2006; 365(1–2): 183–7.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
